IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis 

Peng Zhang et al.

Cell Metab. 2024 Oct 1;36(10):2341-2354.e6. doi: 10.1016/j.cmet.2024.08.012. Epub 2024 Sep 23.

Published on September 24, 2024

Abstract

ABSTRACT

The exponential rise in metabolic dysfunction-associated steatotic liver disease (MASLD) parallels the ever-increasing consumption of energy-dense diets, underscoring the need for effective MASLD-resolving drugs. MASLD pathogenesis is linked to obesity, diabetes, "gut-liver axis" alterations, and defective interleukin-22 (IL-22) signaling. Although barrier-protective IL-22 blunts diet-induced metabolic alterations, inhibits lipid intake, and reverses microbial dysbiosis, obesogenic diets rapidly suppress its production by small intestine-localized innate lymphocytes. This results in STAT3 inhibition in intestinal epithelial cells (IECs) and expansion of the absorptive enterocyte compartment. These MASLD-sustaining aberrations were reversed by administration of recombinant IL-22, which resolved hepatosteatosis, inflammation, fibrosis, and insulin resistance. Exogenous IL-22 exerted its therapeutic effects through its IEC receptor, rather than hepatocytes, activating STAT3 and inhibiting WNT-β-catenin signaling to shrink the absorptive enterocyte compartment. By reversing diet-reinforced macronutrient absorption, the main source of liver lipids, IL-22 signaling restoration represents a potentially effective interception of dietary obesity and MASLD.

PMID:39317186 | PMC:PMC11631175 | DOI:10.1016/j.cmet.2024.08.012

 Read More

← Back to Publications
Mikkola Lea et al.Biochem Biophys Rep. 2026 Nov 9;48:102875. doi: 10.1016/j.bbrep.2026.102875. eCollection 2026 Dec.
Gautier Follain et al.Bio Protoc. 2026 Nov 5;16(21):e5861. doi: 10.21769/BioProtoc.5861. eCollection 2026 Nov 5.
Francesca Bottanelli et al.J Cell Sci. 2026 Nov 1;139(21):jcs265433. doi: 10.1242/jcs.265433. Epub 2026 Nov 12.
Aliaa E Ali et al.Hum Mutat. 2026 Nov 8;2026:8234670. doi: 10.1155/humu/8234670. eCollection 2026.
Marie Christine Goess et al.J Crohns Colitis. 2026 Nov 7;20(11):jjag182. doi: 10.1093/ecco-jcc/jjag182.